Suggested revisions to the current guidelines for the diagnosis and treatment of unstable angina and non-q-wave myocardial infarction by the International Cardiology Forum (ICF) of 1998;Empfehlungen des International Cardiology Forum (ICF) 1998 zur revision der bestehenden richtlinien zur diagnostik und therapie der instabilen angina pectoris und des nicht-transmuralen myokardinfarktes

Zeitschrift fur Kardiologie

Volumn 89, Issue 8, 2000, Pages 706-721

  Gulba, D C ^a   Eichstadt H ^b   Engberding, R ^c   Schulze, M R ^d   Struppler, M ^e   Rutsch, W ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Rehabilitationsklinik Uckermark GmbH   (Germany)

^c Klinikum der Stadt Wolfsburg   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e Kardiologische Praxisgemeinschaft Am Harras   (Germany)

Author keywords

Acute coronary syndrome; Diagnosis; Therapy; Unstable angina

Indexed keywords

DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; PRACTICE GUIDELINE; Q WAVE; REVIEW; TREATMENT INDICATION; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

EID: 0033829224     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003920070200     Document Type: Review

References (85)

1. Unstable angina. A classification
2. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research
3. Management strategies for a better outcome in unstable coronary artery disease
4. Unstable angina and non-Q wave myocardial infarction: Does the clinical diagnosis have therapeutic implications?
5. Insights into the pathogenesis of acute ischemic syndromes
6. Unstable angina: Prognosis of the individual patient
7. Troponin, where do we go from here?
8. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes
9. Cardiac troponin T levels for risk stratification in acute myocardial ischemia
10. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I
11. Prospective study of the role of cardiac troponin T in patients admitted with unstable angina
12. The coagulation cascade: Initiation, maintenance, and regulation
13. Guide to anticoagulant therapy. Part 1: Heparin
14. Aspirin, heparin, or both to treat acute unstable angina
15. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina
16. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4
17. Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparin and a low molecular weight heparin fraction (CY 222)
18. Low molecular weight heparin
19. Direct thrombin inhibitors in cardiovascular medicine
20. Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism)
21. Dalteparin: A low-molecular-weight heparin
22. Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders
23. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders
24. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease
25. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
26. Comparison of two treatment durations (6days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave mayocardial infarction: FRAX.I.S. (FRAXiparine in Ischemic Syndrome)
27. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
28. One-year follow-up of the ESSENCE trial (Enoxaparin versus heparin in unstable angina and NQMI)
29. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: A double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods
30. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial
31. Hirudin and hirudin analogues as new anticoagulant agents
32. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial
33. Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management
34. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia
35. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
36. Seminars in thrombosis, thrombolysis and vascular biology. 3. Platelet activity in cardiovascular disease
37. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
38. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy
39. Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically
40. A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events
41. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
42. A clinical trial comparing three antithromboric-drug regimens after coronary-artery stenting
43. Adverse haematological effects of ticlopidine. Prevention, recognition and management
44. Clopidogrel
45. A randomised, blinded trial of clopidogrel versus aspirin in patients at high risk of ischemic events (CAPRIE)
46. Glycoprotein IIb/IIIa integrin blockade
47. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
48. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
49. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin GPIIb/IIIa blockade with percutaneous coronary intervention
50. Platelet glycoprotein IIB/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
51. Randomised placebo-controlled trial of Abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
52. Inhibition of platelet glycoprotein IIb/ IIIa with eptifibatide in patients with acute coronary syndromes
53. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
54. Heparin use is required for clinical benefit of GIIb/IIIa inhibitor eptifibatide in acute coronary syndromes: Insights from the PURSUIT trial
55. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/ IIIa inhibitor), heparin, or both in unstable angina
56. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II
57. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
58. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group
59. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease
60. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
61. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
62. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program
63. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
64. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates torvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction
65. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/Tex-CAPS
66. Statin trials and goals of cholesterol-lowering therapy
67. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
68. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
69. When to start cholesterol-lowering therapy in patients with coronary heart disease: A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction
70. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB Trial
71. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy
72. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators
73. Trends in the quality of care for Medicare beneficiaries admitted to the hospital with unstable angina
74. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: The MILIS-TIMI experience
75. Improving care for unstable angina patients in a multiple hospital project sponsored by a federally designated quality improvement organization
76. Unstable angina: Specialty-related disparities in implementation of practice guidelines
77. Adherence to national guidlines for drug treatment of suspected acute myocardial infarction: Evidence for undertreatment in women and the elderly
78. Potential impact of evidence-based medicine in acute coronary syndromes: Insights from GUSTO-IIb
79. Grading of angina pectoris
80. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
81. Acute myocardial infarction
82. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
83. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective reandomised multicentre study